Ludwig Link

Welcome letter



Ludwig MIT’s Richard Hynes among winners of the 2022 Lasker Award for his seminal work on integrins

Three Ludwig researchers elected to the National Academy of Medicine

Ludwig Lausanne’s Michal Bassani-Sternberg recognized for her work on cancer antigens



A single protein erects a multifaceted barrier to anti-tumor immunity in mouse models

Functional screen identifies enhancer elements associated with cancer cell fitness and proliferation

iASPP, typically a cancer promoter, helps suppress tumors in inflamed, RAS-driven skin cancers

A nanoparticle boost for radiotherapy and immunotherapy

Noninvasive imaging of tumor-associated macrophages in mice

New link established between the biological clock and the genesis of clear cell kidney cancer

Why a signaling molecule suppresses cancer cell growth only if it’s produced in the nucleus

How high-dose vitamin C kills cancer cells suggests dietary strategy for enhancing therapy

A new approach to measuring protein translation yields translational insights

A cancer cell metabolite that drives malignant growth also inhibits anti-cancer immunity

Two studies take on challenges posed by solid tumors to adoptive T cell therapies

Preclinical study suggests three-drug combination may elicit therapeutic immune responses against GBM

How PI3K signaling, activated by many oncogenes, controls production of a key metabolic cofactor

Novel cell aids development of T regs that suppress immune reactions to gut bacteria

Mapping the dietary sources and preferences of gut bacteria

Spatial organization of purinergic signaling in glioma suggests immunotherapy target

Immune cells can be engineered to counter the inhibitory effects of tumor acidity

Analysis of tumor fibroblast sub-populations reveals new strategies for cancer therapy

An oncogene expressed by a minority of breast cancer cells drives metastasis

A new way to study the altered activity of molecular scissors in living models of cancer

Insights from integrating single cell gene expression and spatial profiling of pancreatic tumors



A conversation with Ed McDermott, president and CEO of the Ludwig Institute



What aspect of tumor metabolism is most promising in terms of a target for novel cancer therapy or immunotherapy?


Download the complete issue:


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?